Baseline patient demographics and disease characteristics
| Characteristics | Group 1: Placebo | Group 2: Golimumab 50 mg | Group 3: Golimumab 100 mg | Total |
|---|---|---|---|---|
| Patients, n | 105 | 101 | 102 | 308 |
| Female, n (%) | 86 (81.9) | 81 (80.2) | 85 (83.3) | 252 (81.8) |
| Age, years | 52.4 (11.1) | 52.9 (11.3) | 51.6 (11.9) | 52.3 (11.4) |
| Body weight, kg | 54.4 (10.4) | 56.2 (12.4) | 53.9 (9.8) | 54.8 (10.9) |
| Duration of RA, years | 9.2 (8.6) | 8.1 (8.4) | 9.4 (8.5) | 8.9 (8.5) |
| Swollen joint count (0–66) | 13.1 (6.9) | 12.6 (5.8) | 12.9 (6.7) | 12.9 (6.5) |
| Tender joint count (0–68) | 14.9 (8.5) | 15.5 (9.0) | 16.6 (10.2) | 15.7 (9.3) |
| Patient's assessment of pain (VAS; 0–100 mm) | 55.2 (24.5) | 55.6 (22.3) | 57.5 (23.1) | 56.1 (23.3) |
| Patient's global assessment (VAS; 0–100 mm) | 54.3 (25.4) | 54.3 (23.7) | 53.9 (24.5) | 54.2 (24.5) |
| Physician's global assessment (VAS; 0–100 mm) | 58.8 (17.8) | 58.4 (18.1) | 59.6 (18.3) | 58.9 (18.0) |
| CRP, mg/dl | 2.5 (2.5) | 2.2 (2.5) | 2.6 (2.8) | 2.5 (2.6) |
| DAS28-ESR | 5.9 (1.0) | 5.8 (1.1) | 6.0 (1.0) | 5.9 (1.0) |
| HAQ-DI (0-3) | 1.0 (0.6) | 1.1 (0.6) | 1.0 (0.6) | 1.0 (0.6) |
Data are presented as mean (SD) unless otherwise noted.
Results include data for all randomised patients who received at least one administration of the study agent and had available efficacy data.
CRP, C-reactive protein; DAS28-ESR, 28-joint Disease Activity Score using erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; RA, rheumatoid arthritis; VAS, visual analogue scale.